Mode
Text Size
Log in / Sign up
Phase 3 N=194 Randomized Treatment

Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery

Cognitive/Functional Effects · Metastatic Cancer · Neurotoxicity · Radiation Toxicity · Unspecified Adult Solid Tumor, Protocol Specific

Enrolled (actual)
194
Serious AEs
17.8%
Results posted
Jul 2018
Primary outcome: Primary: Cognitive Deterioration Free Survival Post-radiation in Patients Who Received SRS Compared to Patients Who Received WBRT — 3.0; 3.7 Months — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
stereotactic radiosurgery (Radiation); whole-brain radiation therapy (Radiation)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Alliance for Clinical Trials in Oncology
Primary completion
Aug 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Cognitive Deterioration Free Survival Post-radiation in Patients Who Received SRS Compared to Patients Who Received WBRT
3.0; 3.7 <0.0001 sig
PRIMARY
Overall Survival
11.6; 12.2 0.70
SECONDARY
Local Control of the Surgical Bed
87.1; 80.4 0.00068 sig
SECONDARY
Time to CNS Failure in These Patients
27.5; 6.4
SECONDARY
Change in Quality-of-life at 6 Months
4; 6; 24; 33; 17; 12 0.31

Summary

RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether stereotactic radiosurgery is more effective than whole-brain radiation therapy in treating patients with brain metastases that have been removed by surgery. PURPOSE: This randomized phase III trial studies how well stereotactic radiosurgery works compared to whole-brain radiation therapy in treating patients with brain metastases that have been removed by surgery.

Eligibility Criteria

Pre-registration Inclusion Criteria:

  • Number of Brain Metastases - Four or fewer brain metastases (as defined on the pre-operative MRI or CT brain scan) and status post resection of one of the lesions.
  • Non-CNS Primary Site - Pathology from the resected brain metastasis must be consistent with a non-central nervous system primary site. Note: Patients with or without active disease outside the nervous system are eligible (including patients with unknown primaries), as long as the pathology from the brain is consistent with a non-central nervous system primary site.
  • Size of Metastases - Any unresected lesions must measure < 3.0 cm in maximal extent on the contrasted MRI or CT brain scan obtained ≤ 35 days prior to pre-registration. The unresected lesions will be treated with SRS as outlined in the treatment section of the protocol. Note: The metastases size restriction does not apply to the resected brain metastasis; with resected brain metastases only surgical cavity size determines eligibility.
  • Size of Resection Cavity - Resection cavity must measure <5.0 cm in maximal extent on the post-operative MRI or CT brain scan obtained ≤35 days prior to pre-registration.

Note: It is permissible for the resection of a dominant brain metastasis to include a smaller "satellite" metastasis as long as the single resection cavity is less than the maximum size requirements.

  • Tumor Staging Procedures - All standard tumor-staging procedures necessary to define baseline extra cranial disease status completed ≤42 days prior to pre-registration.
  • Treatment with Gamma Knife or Radiosurgery - Able to be treated with either a gamma knife or a linear accelerator-based radiosurgery system.
  • Age ≥ 18 years
  • Neurocognitive Testing - Willing and able to complete neurocognitive testing without assistance from family and companions. Note: Because neurocognitive testing is one of the primary goals of this study, patients must be able to utilize English language booklets (and/or French booklets if enrolled in Canada).
  • Quality of Life (QOL) Questionnaires - Willing and able to complete QOL by themselves or with assistance
  • ECOG Performance Status - ECOG Performance Status (PS) 0, 1, or 2.
  • SRS Credentialed by IROC Houston Quality Assurance - The site's SRS facility is IROC Houston Quality Assurance approved.
  • Neurocognitive Testing Credentialing - The site study team member performing neurocognitive testing of patients must have credentialing confirming completion of the neurocognitive testing training of the protocol.
  • Written Informed Consent - Provide written informed consent
  • Mandatory Samples for Correlative Tests - Willing to provide mandatory blood and urine samples for correlative research purposes.

Pre-registration Exclusion Criteria:

  • Pregnancy, Nursing and Contraception - pregnant women, nursing women and men or women of childbearing potential who are unwilling to employ adequate contraception throughout the study and for men for up to 3 months after completing treatment.
  • Prior Cranial Radiation Therapy
  • MRI or CT Scans - Inability to complete a MRI or CT scan with contrast of the head.
  • Gadolinium Allergy - Known allergy to gadolinium.
  • Cytotoxic Chemotherapy - Planned cytotoxic chemotherapy during the SRS or WBRT.
  • Other Tumor Types - Primary germ cell tumor, small cell carcinoma, or lymphoma
  • Leptomeningeal Metastasis - Widespread definitive leptomeningeal metastasis
  • Location of Brain Metastasis - A brain metastasis that is located ≤ 5 mm of the optic chiasm or within the brainstem.

Randomization Inclusion Criteria:

  • Number of Unresected Lesions - Post-operative MRI or CT scan confirmed zero, one, two or three unresected lesions.

1.1 Each unresected lesion must measure ≤ 3.0 cm in maximal extent on the contrasted post-operative MRI or CT brain scan.

1.2 Note: The pre-registration, post-operative, brain scan may be used for the randomization scan if obtained ≤ 28 days prior to randomi

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01372774). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search